Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis

Inflammation and Allergy - Drug Targets

Volumn 12, Issue 1, 2013, Pages 38-45

  Gallego Pinazo, Roberto ^a   Dolz Marco, Rosa ^a   Martínez Castillo, Sebastián ^a   Arévalo, J Fernando ^b,c   Díaz Llopis, Manuel ^a,d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Anti relapse treatment; Biological therapies; Immunosupressive treatment; Intravitreal methotrexate; Intravitreous corticosteroid deposits; Non infectious uveitis; Therapeutic stages

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CALCIUM; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; EFALIZUMAB; ETANERCEPT; FLUOCINOLONE ACETONIDE; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RISK; CATARACT; DIABETES MELLITUS; DIARRHEA; DRUG DOSE REDUCTION; ENDOPHTHALMITIS; FOLLOW UP; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; HAIR LOSS; HEMORRHAGIC CYSTITIS; HEPATITIS; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; INFERTILITY; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; LIVER TOXICITY; LYMPHOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PNEUMONIA; RETINA MACULA EDEMA; REVIEW; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SYSTEMIC THERAPY; TREMOR; UVEITIS;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84875939534     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528111312010006     Document Type: Review

References (33)

1. Cunningham, M.A.; Edelman, J.L.; Kaushal, S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv. Ophthalmol., 2008, 53(2), 139-149.
2. Wang, L.C.; Yang, C.M. Sterile endophtlamitis after intravitreal injection of triamcinolone acetonide. Ocul. Immunol. Inflamm., 2005, 13(4), 295-300.
3. Sallam, A.; Taylor SR.; Lightman, S. Review and update of intraocular therapy in noninfectious uveitis. Curr. Opin. Ophthalmol., 2011, 22(6), 517-522.
4. Jabs, D.A.; Rosenbaum, J.T.; Foster, C.S.; Holland, G.N.; Jaffe, G.J.; Louie, J.S.; Nussenblatt, R.B.; Stiehm, R.; Tessler, H.; Van Gelder, R.N.; Whitup, S.M.; Yocum, D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol., 2000, 130(4), 492-513.
5. Pascual, A.M.; Boscá, I.; Coret, F.; Escutia, M.; Bernat, A.; Casanova, B. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and expanded disability status scale. Eur. J. Neurol., 2008, 15(3), 284-288.
6. Lobo, A.M.; Sobrin, L.; Papaliodis, G.N. Drug delivery options for the treatment of ocular inflammation. Semin. Ophthalmol., 2010, 25(5-6), 283-288.
7. Brumm, M.V.; Nguyen, Q.D. Fluocinolone acetonide intravitreal sustained release device-a new addition to the armamentarium of uveitic management. Int. J. Nanomed., 2007, 2(1), 55-64.
8. Callanan, D.G.; Jaffe, G.J.; Martin, D.F.; Pearson, P.A.; Comstock, T.L. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol., 2008, 126(9), 1191-201.
9. Jaffe, G.J.; Martin, D.; Callanan, D.; Pearson, P.A.; Levy, B.; Comstock, T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology, 2006, 113(6), 1020-1027.
10. Goldstein, D.A.; Godfrey, D.G.; Hall, A.; Callanan, D.G., Jaffe, G.J.; Pearson, P.A.; Usner, D.W.; Comstock, T.L. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch. Ophthalmol., 2007, 125(11), 1478-1485.
11. Campochiaro, P.A.; Brown, D.M.; Pearson, A.; Ciulla, T.; Boyer, D.; Holz, F.G.; Tolentino, M.; Gupta, A.; Duarte, L.; Madreperla, S.; Gonder, J.; Kapik, B.; Billman, K.; Kane, F.E.; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology, 2011, 118(4), 626-35. e2.
12. London, N.J.; Chiang, A.; Haller, J.A. The dexamethasone drug delivery system: indications and evidence. Adv. Ther., 2011, 28(5), 351-66.
13. Lowder, C.; Belfort. R. Jr.; Lightman, S.; Foster, C.S.; Robinson, M.R.; Schiffman, R.M.; Li, X.Y.; Cui, H.; Whitcup, S.M.; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol., 2011, 129(5), 545-53.
14. Díaz-Llopis, M.; Cervera, M.; Menezo, J.L. Cyclosporin A treatment of Behçet's disease: a long-term study. Curr. Eye Res., 1990, 9(Suppl), 17-23.
15. Figueroa, M.S.; Ciancas, E.; Orte, L. Long-term follow-up of tacrolimus treatment in immune posterior uveitis. Eur. J. Ophthalmol., 2007, 17(1), 69-74.
16. Roblin, X.; Biroulet, L.P.; Phelip, J.M.; Nancey, S.; Florie, B. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am. J. Gastroenterol., 2008, 103(12), 3115-22.
17. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet, 1995, 345(8961), 1321-1325.
18. Goldstein, D.A.; Fontanilla, F.A.; Kaul, S.; Sahin, O.; Tessler, H.H. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology, 2002, 109(2), 370-377.
19. Diaz-Llopis, M.; García-Delpech, S.; Salom, D.; Udaondo, P.; Hernández-Garfella, M.; Bosch-Morell, F.; Quijada, A.; Romero, F.J. Adalimumab therapy for refractory uveitis: a pilot study. J. Ocul. Pharmacol. Ther., 2008, 24(3), 351-361.
20. Cordero-Coma, M.; Salom, D.; Díaz-Llopis, M.; López-Prats, M.J.; Calleja, S. Golimumab for uveitis. Ophthalmology, 2011, 118(9), 1892. e3-4.
21. Dick, A.D.; Meyer, P.; James, T.; Forrester, J.V.; Hale, G.; Waldmann, H.; Isaacs, J.D. Campath-1H therapy in refractory ocular inflammatory disease. Br. J. Ophthalmol., 2000, 84(1), 107-109.
22. Sadreddini, S.; Noshad, H.; Molaeefard, M.; Noshad, R. Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod. Rheumatol., 2008, 18(3), 306-308.
23. Dolz-Marco, R.; Gallego-Pinazo, R.; Díaz-Llopis, M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J. Ophthalmic. Inflamm. Infect., 2011, 1(4), 177-180.
24. Faia, L.J.; Yeh, S.; Wroblewski, K.J.; Lew, J.; Nussenblatt, R.B. Efalizumab (Raptiva) for the Treatment of Macular Edema Associated With Intermediate or Posterior Uveitis American Academy of Ophthalmology Annual Meeting, Scientific poster communication (PO138), Atlanta, 2008.
25. Muselier, A.; Bielefeld, P.; Bidot, S.; Vinit, J.; Besancenot, J.F.; Bron, A. Efficacy of tocilizumab in two patients with anti-TNFalpha refractory uveitis. Ocul. Immunol. Inflamm., 2011, 19(5), 382-383.
26. Tranos, P.G.; Wickregmashinge S.S.; Strangos, N.T.; Macular Edema. Surv. Ophthalmol., 2004, 49, 470-490.
27. Mackensen, F.; Heinz, C.; Becker, M.D.; Heiligenhaus, A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina, 2008, 28(1), 41-45.
28. Amselem, L.; Díaz-Llopis, M.; Cervera, E.; Salom, D.; Fuste, F.; Montero, J. Pegaptanib sodium for acute retinal necrosis-induced macular oedema. Acta. Ophthalmol., 2010, 88(2), e42-43.
29. Androudi, S.; Tsironi, E.; Kalogeropoulos, C.; Theodoridou, A.; Brazitikos, P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology, 2010, 117(8), 1612-1616.
30. Yeh, S.; Wilson, D.J. Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma. Eye (Lond)., 2010, 24(10), 1625-1627.
31. Melo, G.B., Moraes Filho, M.N., Rodrigues, E.B.; Regatieri, C.V.; Dreyfuss, J.L., Penha, F.M.; Pinheiro, M.M.; Coimbra, R.C.; Haapalainen, E.F.; Farah, M.E. Toxicity and retinal penetration of infliximab in primates. Retina, 2012, 32(3), 606-612.
32. Ekdawi, N.S.; Pulido, J.S.; Itty, S.; Marler, R.J.; Herman, D.C.; Hardwig, P.; Mohney, B.G.; Valyi-Nagy, T., Shukla, D. Intravitreal alemtuzumab penetrates full-thickness retina in rabbit eyes. Retina, 2009, 29(10), 1532-1534.
33. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina, 2010, 30(9), 1530-1535.